Prospective follow-up of 3,228 patients suffering from clinical benign prostatic hyperplasia (BPH) treated by alfuzosin in general practice for 3 years;Suivi prospectif de 3.228 patients souffrant d'une hypertrophie bénigne de la prostate (HBP) clinique traités pendant 3 ans par l'alfuzosine en médecine générale

Progres en Urologie

Volumn 9, Issue 2, 1999, Pages 271-280

  Lukacs, Bertrand ^a   Grange, Jean Claude ^b   Comet, Denis ^c   Mc Carthy, C Christine ^b  

^a HÔPITAL TENON   (France)

^b Laboratoires Synthélabo   (France)

^c Axonal Biostatem   (France)

Author keywords

Alpha adrenergic antagonist; BPH; Long term outcome; Medical treatment of BPH; Quality of life

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; QUINAZOLINE DERIVATIVE;

AGED; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; FOLLOW UP; FRANCE; HUMAN; MALE; MULTICENTER STUDY; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; PROSTATE HYPERTROPHY; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; QUESTIONNAIRE; SEXUAL BEHAVIOR;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; AGED, 80 AND OVER; COHORT STUDIES; FOLLOW-UP STUDIES; FRANCE; HUMANS; MALE; PROSPECTIVE STUDIES; PROSTATIC HYPERPLASIA; QUALITY OF LIFE; QUESTIONNAIRES; QUINAZOLINES; SEXUAL BEHAVIOR;

EID: 0033113857     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. BARRY M.J., FOWLER F.J. The methodology for evaluating the subjective outcomes of treatment for benign prostatic hyperplasia. Adv. Urol., 1993, 6, 83-99.
2. BARRY M.J., FOWLER F.J., O'LEARY M.P. et al. The American Urological Association Symptom Index for benign prostatic hyperplasia. J. Urol., 1992, 148, 1549-1557.
3. BARRY M.J., FOWLER F.J., O'LEARY M.P., BRUSKEWITZ R.C., HOLTGREWE H.L., MEBUST W.K. Measuring disease-specific health status in men with benign prostatic hyperplasia. Med. Care, 1995, 33, A5145.
4. BARRY M.J., FOWLER F.J., O'LEARY M.P., BRUSKEWITZ R.C., HOLTGREWE H.L., MEBUST W.K., COCKETT A.T.K. The American Urological Association Symptom Index for Benign prostatic hyperplasia. J. Urol., 1992, 148, 1549-1557.
5. BARRY M.J., FOWLER F.J., O'LEARY M.P., BRUSKEWITZ R.C., HOLTGREWE H.L., MEBUST W.K. Correlation of the American Urological Association symptom index with self-admin stered versions of the Madsen-Iversen, Boyarsky and Maine Medical Assessment Program Symptoms Indexes. J. Urol., 1992, 148, 1558-1563.
6. BOYARSKY S., JONES G., PAULSON D.F., PROUT G.R. A new look at bladder neck obstruction by the Food and Drug Administration regulators : guidelines for investigation of benign prostatic hypertrophy. Trans. Amer. Ass. Genito-Urin. Surg., 1977, 68, 29-32.
7. BOYLE P., MAISONNEUVE P., STEG A. Decrease in mortality from benign prostatic hyperplasia: a major unheralded health triumph. J. Urol., 1996, 155, 176-180.
8. BRESLIN D.S., MUECKE E.C., RECKLER J.M., FRACCHIA J.A. Changing trends in the management of prostatic disease in a single private practice: a 5-year follow-up. J. Urol., 1993, 150, 346-350.
9. BUZELIN J.M., ROTH S., GEFFRIAUD-RICOUARD C., DELAUCHE-CAVALLIER M.C. and the Algebi study group. Efficacy and safety of sustained-release alfuzosin 5mg in patients with benign prastatic hyperplasia. Eur. Urol., 1997, 31, 190-198.
10. BUZELIN J.M., DELAUCHE-CAVALLIER M.C., ROTH S., GEFFRIAUD-RICOUARD C., SANTONI J.P. Clinical uroselectivity : evidence from patients treated with slow-release alfuzosin for symptomatic benign prostatic obstruction. Br. J. Urol., 1997, 79, 898-906.
11. COCKETT A.T.K., KHOURY S., ASO Y., CHATELAIN C., DENIS L., GRIFFITHS K., MURPHY G. eds. Proceedings of the Second International Consultation on Benign Prostatic Hyperplasia (BPH). Paris : SCI, 1992, 351.
12. COCKETT A.T.K., KHOURY S., ASO Y., CHATELAIN C., DENIS L., GRIFFITHS K., MURPHY D. eds. Proceedings of the Third International Consultation on Benign Prostatic Hyperplasia (BPH). Paris, SCI, 1996, 651.
13. DIOKNO A.C., BROCK B.M., BROWN M.B., HERZOG A.R. Prevalence of urinary incontinence and other urological symptoms in the non-institutionalized elderly. J. Urol., 1986, 136, 1022-1025.
14. DOLL H.A., BLACK N.A., FLOOD A.B., McPHERSON K., WILLIAMS G.B., SMITH J.C. Differences in outcome of TURP for benign prostatic hypertrophy between three diagnostic categories. Br. J. Urol., 1993, 72, 322-330.
15. DOWD J.B. Editorial Benign Prostatic Hyperplasia: Practice Makes Perfect. J. Urol., 1996, 155, 190.
16. ERI L.M., TVETER K.J. Blockade in the treatment of symptomatic benign prostatic hyperplasia. J. Urol., 1995, 154, 923-934.
17. FOWLER F.J., WENNBERG J.E., TIMOTHY R.P., BARRY M.J., MULLEY A.G., HANLEY D. Symptom status and quality of life following prostatectomy. J. Am. Med. Assoc., 1988, 259, 3018-3022.
18. GIRMAN C.J., KOLMAN C. LISS C.L., BOLOGNESE J.A., BINKOWITZ B.S., STONER E. Effects of finasteride on Health Related Quality of Life in Men with Symptomatic Benign Prostatic Hyperplasia. The Prostate, 1996, 29, 83-90.
19. GUESS H.A., CHUTE C.G., GARRAWAY W.M., GIRMAN C.J., PANSER L.A., LEE R.J., JACOBSEN S.J., McKELVIE G.B., OESTERLING I.E., LIEBER M.M. Similar levels of urological symptoms have similar impact on Scottish and American men-although Scots report less symptoms. J. Urol., 1993, 150, 1701-1705.
20. JARDIN A., BENSADOUN H., DELAUCHE-CAVALIER M.C., ATTALI P., and the BPH-ALF Group. Alfuzosin for treatment of Benign Prostatic Hypertrophy. Lancet, 1991, 337, 1457-1461.
21. JARDIN A., BENSADOUN H., DELAUCHE-CAVALIER M.C., STALLA-BOURDILLON A., ATTALI P., and the BPHALF Group. Long term treatment of benign prostatic hyperplasia with alfuzosin : a 24-30 month survey. Br. J. Urol., 1994, 74, 579-584.
22. JOLLEYS J.V., DONOVAN J.L., NANCHAHAL K., PETERS T.J., ABRAMS P. Urinary symptoms in the community : how bothersome are they? Br. J. Urol., 1994, 74, 551-555.
23. KIRBY R.S. Are the days of transurethral resection of the prostate for benign prostatic hyperplasia numbered ? Urologists must grasp the future. Br. Med. J., 1994, 309, 716-717.
24. LEPOR H. Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Urology, 1995, 45, 406-413.
25. LEPOR H., KAPLAN S.A., KLIMBERG I., MOBLEY D.F., FAWZY A., GAFFNEY M., ICE K., DIAS N. Doxazosin for benign prostatic hyperplasia : long-term efficacy and safety in hypertensive and normotensive patients. J. Urol., 1997, 157, 525-530.
26. LEPOR H., NIEDER A., FESER J., O'CONNELL C., DIXON C. Effect of terazosin on prostatism in men with normal and abnormal peak urinary flow rates. Urology, 1997, 49, 476-480.
27. LUKACS B., LEPLEGE A., THIBAULT P., JARDIN A. Development, validation and application of a BPH-specific health-related quality of life questionnaire: results of a BPH medical outcome study. In : Cockett A.T.K., Khoury S., Aso Y. et al., : eds. Proceedings of the Third International Consultation on Benign Prostatic Hyperpasia (BPH). Paris, SCI, 1996, 277-280.
28. LUKACS B., LEPLEGE A., MC CARTHY C., COMET D. Construction and validation of a BPH specific health related quality of life scale (with special attention to sexuality),for medical outcome research studies. In : Cockett ATK, Khoury S, Aso Y et al, eds. Proceedings of the second international consultation on benign prostatic hyperplasia (BPH)., Paris, SCI, 1994, 139-143.
29. LUKACS B., LEPLEGE A., THIBAULT P., JARDIN A. Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners : 1-year results. Urology, 1996, 48, 731-740.
30. LUKACS B., COMET D., DOUBLET D., GRANGE J.C., GATTEGNO B. Health Related Quality of Life in BPH patients treated for two years with alfuzosin. J. Epidemiol. Biol., 1997, 2, 203-211.
31. Mc CONNELL J.D., BARRY M.J., BRUSKEWITZ R.C., BUESCHEN A.J., DENTON S;E., H OLTGREWE H.L., LANGE J.L., McCLENENAN B.L., MEBUST W.K., REILLY N.J., ROBERTS R.G., SACKS S.A., WASSON J.H. Benign Prostatic Hyperplasia diagnosis and treatment., Clinical Practice Guideline, number 8. AHCPR Publication No. 94-0582. Rockville, MD: Agency for Health Care Policy and Research, Public Health Service, US Department of Health and Human Services. February 1994, 225.
32. McKELVIE G.B., COLLINS G.N., HEHIR M., ROGERS A.C.N. A study of benign prostatic hyperplasia C a challenge to British urology. Br. J. Urol., 1993, 71, 38-42.
33. MEBUST W.K., BOSCH R., DONOVAN J., OKADA K., O'LEARY M.P., VILLERS A. Symptom evaluation, quality of life and sexuality. In: Cockett ATK, Khoury S, Aso Y et al. Proceedings of the second international consultation on benign prostatic hyperplasia (BPH). Paris, SCI, 1994, pp. 131-138.
34. OESTERLING J.E. Benign prostatic hyperplasia. Medical and minimally invasive treatment options. N. Engl. J. Med .,1995, 332, 99-109.
35. O'LEARY M.P., FOWLER F.J., LENDERKING W.R., BARBER B., SAGNIER P.P., GUESS H.A., BARRY M.J. A brief male sexual function inventory for urology. Urology, 1995, 46, 697-706.
36. ROSIER P.F.W.M., de WILDT M.J.A.M., WIJKSTRA H., DEBRUYNE F.F.M.J., de la ROSETTE J.J.M.C.H. Clinical diagnosis of bladder outlet obstruction in patients with benign prostatic enlargement and lower urinary tract symptoms: development and urodynamics validation of a clinical prostate score for the objective diagnosis of bladder outlet obstruction. J. Urol., 1996, 155, 1649-1654.
37. STEINWACHS D.M. Episode of care framework : utility for medical effectiveness research. In : Medical effectiveness research data methods. Edited by M.L. Grady, H.A. Schwartz. AHCPR Publication No. 92-0056. Rockville, MD : Agency for health care policy and research., June 1992, 161-171.
38. Van MASTRIG T.R., ROLLEMA H.J. The prognostic value of bladder contractility in transurethral resection of the prostate. J. Urol., 1992, 148, 1856-1860.
39. WASSON J.H., REDA D.J., BRUSKEWITZ R.C., ELINSON J., KELLER A.M., HENDERSON W.G. for the Veterans Affairs Cooperative Study Group on transurethral resection of the prostate. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. N. Engl. J. Med., 1995, 332, 75-79.
40. Comparing treatments : Safety, effectiveness, and cost-effectiveness. March 23rd/24th Workshop. FDA - Division of drug marketing, advertising and promotion (DDMAC). Principles for the review of pharmacoeconomic promotion., Script - No 2013, April 4th, 1995.
41. The Department of Veterans Affairs cooperative study of transurethral resection for benign prostatic hyperplasia. A comparison of quality of life with patient reported symptoms and objective findings in men with benign prostatic hyperplasia., J Urol 1993, 150, 1696-1700.